Cambrex Completes Acquisition of Halo Pharma

By Patricia Van Arnum - DCAT Editorial Director

September 14, 2018

Cambrex, a contract manufacturer of small-molecule active pharmaceutical ingredients (APIs), has completed its acquisition of Halo Pharma, a Whippany, New Jersey-headquartered contract development and manufacturing organization, for approximately $425 million.

Cambrex announced the acquisition in July 2018. The addition of adds formulation development and finished dosage manufacturing capabilities to Cambrex’s existing global API manufacturing network.

Halo Pharma operates two GMP-compliant facilities located in Whippany, New Jersey and Montreal, Québec, Canada, comprising 430,000 square feet of plant space. These newly acquired facilities provide formulation development and clinical and commercial manufacturing services, specializing in oral solids, liquids, creams, sterile and non-sterile ointments. The core competencies gained include developing and manufacturing complex and difficult-to-produce formulations, products for pediatric indications, and controlled substances.

Halo’s 450-person workforce will join Cambrex’s 1,200 employees across the US and Europe.

Source: Cambrex